Literature DB >> 28363484

Radiobiological parameters of liver and lung metastases derived from tumor control data of 3719 metastases.

Rainer J Klement1.   

Abstract

BACKGROUND AND
PURPOSE: The radiobiological parameters for liver and lung metastases treated with stereotactic body radiation therapy (SBRT) are poorly defined. This project aimed at estimating these parameters from published tumor control probability (TCP) data, and separately for metastases with colorectal cancer (CRC) and non-CRC histology.
MATERIALS AND METHODS: A total of 62 studies with 89 different treatment prescriptions for a total of 3719 metastases were analyzed in a Bayesian framework using four different radiobiological models: The LQ, mLQ, LQ-L and the regrowth model which accounts for tumor regrowth after SBRT.
RESULTS: Depending on the particular model, α/β ratios in the range 13-23Gy for pulmonary metastases and 16-28Gy for hepatic metastases were estimated. For CRC metastases the estimated α/β ratio was 43.1±4.7Gy compared to 21.6±7.8Gy for non-CRC metastases. Typical isocenter dose prescriptions of 3×12Gy, 3×14.5Gy and 3×17Gy applied within 5days were predicted sufficient to control 90% of lung, liver and CRC metastases after 1yr, respectively.
CONCLUSIONS: α/β ratios for liver and lung metastases are higher than the usually assumed 10Gy. Differences between CRC and non-CRC histology were found. Future studies confirming these findings in individual patient data are needed.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Bayesian modeling; Metastases; Radiobiology; SBRT; Tumor control probability

Mesh:

Year:  2017        PMID: 28363484     DOI: 10.1016/j.radonc.2017.03.014

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  10 in total

1.  Prediction of Tumor Control in 90Y Radioembolization by Logit Models with PET/CT-Based Dose Metrics.

Authors:  Yuni K Dewaraja; Theresa Devasia; Ravi K Kaza; Justin K Mikell; Dawn Owen; Peter L Roberson; Matthew J Schipper
Journal:  J Nucl Med       Date:  2019-05-30       Impact factor: 10.057

2.  Breathing-motion-compensated robotic guided stereotactic body radiation therapy : Patterns of failure analysis.

Authors:  Susanne Stera; Panagiotis Balermpas; Mark K H Chan; Stefan Huttenlocher; Stefan Wurster; Christian Keller; Detlef Imhoff; Dirk Rades; Jürgen Dunst; Claus Rödel; Guido Hildebrandt; Oliver Blanck
Journal:  Strahlenther Onkol       Date:  2017-09-05       Impact factor: 3.621

3.  Stereotactic Body Radiation Therapy (SBRT) Using CyberKnife in Oligometastatic Cancer Patients; Retrospective Evaluation, Single Institution Experience.

Authors:  Abdullah Alsuhaibani; Ahmed Elashwah; Abdullah Alkafi; Camelia Constantinescus; Faisal ALzorkany
Journal:  J Gastrointest Cancer       Date:  2019-12

4.  Radiofrequency Ablation versus Stereotactic Body Radiation Therapy in the Treatment of Colorectal Cancer Liver Metastases.

Authors:  Jesang Yu; Dong Hwan Kim; Jungbok Lee; Yong Moon Shin; Jong Hoon Kim; Sang Min Yoon; Jinhong Jung; Jin Cheon Kim; Chang Sik Yu; Seok-Byung Lim; In Ja Park; Tae Won Kim; Yong Sang Hong; Sun Young Kim; Jeong Eun Kim; Jin-Hong Park; So Yeon Kim
Journal:  Cancer Res Treat       Date:  2021-10-13       Impact factor: 5.036

5.  The SBRT database initiative of the German Society for Radiation Oncology (DEGRO): patterns of care and outcome analysis of stereotactic body radiotherapy (SBRT) for liver oligometastases in 474 patients with 623 metastases.

Authors:  N Andratschke; H Alheid; M Allgäuer; G Becker; O Blanck; J Boda-Heggemann; T Brunner; M Duma; S Gerum; M Guckenberger; G Hildebrandt; R J Klement; V Lewitzki; C Ostheimer; A Papachristofilou; C Petersen; T Schneider; R Semrau; S Wachter; D Habermehl
Journal:  BMC Cancer       Date:  2018-03-13       Impact factor: 4.430

6.  Phase II trial on SBRT for unresectable liver metastases: long-term outcome and prognostic factors of survival after 5 years of follow-up.

Authors:  Marta Scorsetti; Tiziana Comito; Elena Clerici; Ciro Franzese; Angelo Tozzi; Cristina Iftode; Lucia Di Brina; Pierina Navarria; Pietro Mancosu; Giacomo Reggiori; Antonella Fogliata; Stefano Tomatis; Guido Torzilli; Luca Cozzi
Journal:  Radiat Oncol       Date:  2018-11-26       Impact factor: 3.481

Review 7.  Magnetic Resonance Imaging-Guided Adaptive Radiotherapy for Colorectal Liver Metastases.

Authors:  Paul B Romesser; Neelam Tyagi; Christopher H Crane
Journal:  Cancers (Basel)       Date:  2021-04-01       Impact factor: 6.639

8.  Radiotherapeutic treatment options for oligotopic malignant liver lesions.

Authors:  Peter Wust; Marcus Beck; Robert Dabrowski; Oliver Neumann; Sebastian Zschaeck; David Kaul; Dominik P Modest; Carmen Stromberger; Bernhard Gebauer; Pirus Ghadjar
Journal:  Radiat Oncol       Date:  2021-03-16       Impact factor: 3.481

Review 9.  Stereotactic radiotherapy for lung oligometastases.

Authors:  Lorenzo Falcinelli; Claudia Menichelli; Franco Casamassima; Cynthia Aristei; Simona Borghesi; Gianluca Ingrosso; Lorena Draghini; Angiolo Tagliagambe; Serena Badellino; Michela Buglione di Monale E Bastia
Journal:  Rep Pract Oncol Radiother       Date:  2022-03-22

10.  Stereotactic Radiotherapy for Pulmonary Oligometastases From Colorectal Cancer: A Systematic Review and Meta-Analysis.

Authors:  Keiichi Jingu; Haruo Matsushita; Takaya Yamamoto; Rei Umezawa; Yojiro Ishikawa; Noriyoshi Takahashi; Yu Katagiri; Kazuya Takeda; Noriyuki Kadoya
Journal:  Technol Cancer Res Treat       Date:  2018-01-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.